India  

Moderna Working on Vaccine Booster That Targets the Omicron Variant

Video Credit: Wibbitz Top Stories - Duration: 01:30s - Published
Moderna Working on Vaccine Booster That Targets the Omicron Variant

Moderna Working on Vaccine Booster That Targets the Omicron Variant

Moderna Working on , Vaccine Booster That Targets, the Omicron Variant.

The Associated Press reports that Moderna is developing an updated COVID-19 booster that offers protection against the omicron variant.

On April 19, the pharmaceutical company released data suggesting that work on the updated booster was making progress.

Prior to the emergence of omicron, Moderna had been developing a booster with added protection against the beta variant of coronavirus.

According to the company, people who received that specific booster produced more antibodies capable of fighting a number of variants.

AP reports that the omicron variant is able to more easily slip past the immune system's defenses than the original coronavirus.

According to health officials, distributing boosters every few months does not present a practical solution to the mutating virus.

As a result, Moderna and its rival Pfizer are testing "bivalent" shots which mixes each company's original vaccine with an updated omicron version.

.

As a result, Moderna and its rival Pfizer are testing "bivalent" shots which mixes each company's original vaccine with an updated omicron version.

.

Moderna's bivalent shot reportedly includes 32 variant mutations of the coronavirus.

Studies on the new bivalent shots are currently underway in the United States and Britain.

.

Results from the studies are expected by late June


You Might Like


💡 newsR Knowledge: Other News Mentions

Moderna COVID-19 vaccine Moderna COVID-19 vaccine RNA COVID-19 vaccine

FDA Calls for Fall COVID Boosters To Target Omicron Subvariants [Video]

FDA Calls for Fall COVID Boosters To Target Omicron Subvariants

FDA Calls for Fall COVID Boosters , To Target Omicron Subvariants. NBC News reports that on June 30, the Food and Drug Administration asked vaccine makers to modify upcoming booster shots to target subvariants of Omicron. The Omicron subvariants the agency wishes to target are BA.4 and BA.5. Officials have called on vaccine makers Pfizer-BioNTech and Moderna to produce bivalent vaccines, . which are intended to target the original strain of COVID-19 as well as its subvariants. As we move into the fall and winter, it is critical that we have safe and effective vaccine boosters that can provide protection... , Dr. Peter Marks, FDA, via NBC News. ... against circulating and emerging variants to prevent the most severe consequences of COVID-19. , Dr. Peter Marks, FDA, via NBC News. As of the week ending June 25, Omicron subvariants BA.4 and BA.5 were responsible for 52% of all new cases of COVID-19. Per the Centers for Disease Control and Prevention, BA.1, the first variant of Omicron, caused 0% of new cases. Pfizer and Moderna have thus far altered vaccines to target the original strain of COVID-19 and BA.1. which increased the immune response to earlier iterations, though both have waned in their efficacy against BA.4 and BA.5

Credit: Wibbitz Top Stories    Duration: 01:30Published
Elmo Gets Vaccinated Against COVID [Video]

Elmo Gets Vaccinated Against COVID

Elmo Gets Vaccinated , Against COVID. Earlier this month, Moderna and Pfizer/BioNTech vaccines were given emergency use authorization for children as young as six months old. The CDC also signed off on the shots for kids under 5. On June 28, 'Sesame Street' issued a public service announcement to spread the word. Elmo's dad, Louie, addressed getting his son vaccinated. Elmo's dad, Louie, addressed getting his son vaccinated. Was it safe? Was it the right decision?’ I talked to our pediatrician so I could make the right choice. I learned that Elmo getting vaccinated is the best way to keep himself, our friends, neighbors and everyone else healthy and enjoying the things they love, Louie, Elmo's dad, via 'Sesame Street'. According to a Kaiser Family Foundation Vaccine Monitor survey conducted in April, 38% of parents wanted to "wait and see" before vaccinating their young kids. According to a Kaiser Family Foundation Vaccine Monitor survey conducted in April, 38% of parents wanted to "wait and see" before vaccinating their young kids. Jeanette Betancourt, senior vice president of U.S. social impact at Sesame Workshop, issued a statement about the PSA. We hope that Louie and Elmo will inspire parents and caregivers across the country to speak with their healthcare providers and seek out information to learn about how the COVID-19 vaccines can keep young children and their families healthy, Jeanette Betancourt, senior vice president of U.S. social impact at Sesame Workshop, via CNN. The CDC reports that as of June 22, 30% of kids between the ages of 5 and 11 and 60% between the ages of 12 and 17 were fully vaccinated. The CDC reports that as of June 22, 30% of kids between the ages of 5 and 11 and 60% between the ages of 12 and 17 were fully vaccinated

Credit: Wibbitz Top Stories    Duration: 01:31Published
FDA Panel Endorses COVID Vaccines for Children Under 5 [Video]

FDA Panel Endorses COVID Vaccines for Children Under 5

FDA Panel , Endorses COVID Vaccines, for Children Under 5. On June 15, an advisory panel to the United States Food and Drug Administration voted to recommend two COVID-19 vaccines for kids ages 5 and under. Yahoo reports that both Pfizer/BioNTech and Moderna were under review by the panel. . The unanimous FDA panel vote is the first step in what is predicted to be a quick authorization process. According to Yahoo, data from trials shows that both vaccines continue to protect against severe disease, hospitalization and death. According to Yahoo, data from trials shows that both vaccines continue to protect against severe disease, hospitalization and death. Yahoo reports that parents now have two options for how to vaccinate their children. Pfizer's vaccine for kids is delivered in three, three-microgram doses, while Moderna's vaccine is delivered in two shots of a 25-microgram dose. Our robust clinical study shows that three doses can provide protection for the circulating Omicron variant and offers promise for protection against potential future waves of COVID-19, Dr. Bill Gruber, Pfizer's Vaccine Clinical Research and Development head, via Yahoo. Our robust clinical study shows that three doses can provide protection for the circulating Omicron variant and offers promise for protection against potential future waves of COVID-19, Dr. Bill Gruber, Pfizer's Vaccine Clinical Research and Development head, via Yahoo. The committee’s support today is imperative to providing a critical tool for pediatricians, parents, and caregivers who eagerly await an option for children under five, Dr. Bill Gruber, Pfizer's Vaccine Clinical Research and Development head, via Yahoo. Both companies are now awaiting approval from the FDA and the CDC which will hold an advisory committee meeting on the topic over the weekend.

Credit: Wibbitz Top Stories    Duration: 01:30Published
Moderna Says New Booster Shows 'Superior' Omicron Response [Video]

Moderna Says New Booster Shows 'Superior' Omicron Response

Moderna Says New Booster , Shows 'Superior' Omicron Response. NPR reports Moderna claims its most recent vaccine candidate has shown a "superior neutralizing antibody response" when compared to its first vaccine. It is "bivalent," engineered to target two different antigens. Per NPR, Moderna intends to make its newest booster available in fall 2022. We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer. , Stéphane Bancel, Moderna CEO, via statement. Due to a higher antibody response, Moderna believes its newest vaccine will offer protection that is "more durable over time" against Omicron. Due to a higher antibody response, Moderna believes its newest vaccine will offer protection that is "more durable over time" against Omicron. Moderna officials think their new vaccine could potentially offer protection for one year. As new variants continuously arise, Moderna officials hope the new bivalent vaccine can counter the more contagious strains taking hold in the United States. As new variants continuously arise, Moderna officials hope the new bivalent vaccine can counter the more contagious strains taking hold in the United States. According to the Centers for Disease Control and Prevention (CDC), two new subvariants of Omicron, BA.4 and BA.5, are spreading quickly across the country. Experts say another wave of coronavirus is bound to occur next winter as cold weather drives citizens back indoors

Credit: Wibbitz Top Stories    Duration: 01:30Published

SARS-CoV-2 Omicron variant SARS-CoV-2 Omicron variant November 2021 variant of SARS-CoV-2

New sub-variant of Omicron detected in 10 Indian states, alerts Israeli expert | Oneindia News *News [Video]

New sub-variant of Omicron detected in 10 Indian states, alerts Israeli expert | Oneindia News *News

As the cases of the Covid-19 virus are once again on the rise in the country an Israeli health expert on Sunday said that India has a new sub-variant of the highly contagious Omicron lineage of coronavirus, BA.2.75. #Omicron #OmicronSubvariant #Covid-19inIndia

Credit: Oneindia    Duration: 01:34Published
'We should not be complacent' over COVID-19 rise on the continent, WHO Europe chief says [Video]

'We should not be complacent' over COVID-19 rise on the continent, WHO Europe chief says

Many European countries are experiencing a surge in new COVID-19 infections, with the more transmissible Omicron subvariant BA.5 spreading across the continent.

Credit: euronews (in English)    Duration: 01:55Published

Pfizer Pfizer American multinational pharmaceutical and biotechnology corporation

Pfizer Says Updated COVID-19 Shot Effective Against Omicron [Video]

Pfizer Says Updated COVID-19 Shot Effective Against Omicron

Pfizer Says Updated COVID-19 Shot , Effective Against Omicron. NBC News reports Pfizer announced on June 25 that its updated coronavirus vaccine better targets the omicron variant. Experts say while current vaccines offer ample protection against new variants, . their effectiveness has waned in the age of omicron. The Food and Drug Administration has considered ordering altered vaccines, . hoping a modified recipe could offer more protection when coronavirus surges again this fall and winter. Pfizer says after studying over 1,200 adults who had received three vaccine doses. officials say each of their vaccines showed a substantial increase in omicron-resistant antibodies. Based on these data, we believe we have two very strong omicron- adapted candidates. , statement from Pfizer CEO Albert Bourla, via NBC News. Pfizer's tweaked shot shows a 9 to 11-fold increase in omicron-fighting antibodies. almost 1.5 times higher than the company's initial dose

Credit: Wibbitz Top Stories    Duration: 01:30Published
Pfizer's COVID Vaccine for Kids Under 5 Moves Closer to FDA Approval [Video]

Pfizer's COVID Vaccine for Kids Under 5 Moves Closer to FDA Approval

Pfizer's COVID Vaccine for Kids Under 5 , Moves Closer to FDA Approval . Pfizer announced on June 1 that its application to the Food and Drug Administration (FDA) for the vaccine was complete. Pfizer announced on June 1 that its application to the Food and Drug Administration (FDA) for the vaccine was complete. The three-dose vaccine is for children between the ages of six months and five years. Pfizer released a statement detailing the application. Pfizer and BioNTech completed a rolling application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA)... , Pfizer Statement, via ABC News. ... of the 3-µg [microgram] dose of the Pfizer-BioNTech COVID-19 Vaccine.., Pfizer Statement, via ABC News. ... for children 6 months through 4 years of age (also referred to as 6 months to under 5 years of age) on June 1, 2022, Pfizer Statement, via ABC News. Pfizer reported an 80 percent effectiveness rate in children in May. The FDA also released a statement on June 1, confirming that the agency had accepted the Pfizer application. We recognize parents are anxious to have their young children vaccinated against COVID-19... , FDA Statement, via ABC News. ... and while the FDA cannot predict how long its evaluation of the data and information will take, , FDA Statement, via ABC News. ... we will review any EUA request we receive as quickly as possible using a science-based approach, FDA Statement, via ABC News. According to a poll conducted by the Kaiser Family Foundation in April of this year. ... just 18 percent of parents intend to have their children vaccinated once the vaccine is approved. 27 percent of parents stated that they will "definitely not" vaccinate their children against COVID

Credit: Wibbitz Top Stories    Duration: 01:31Published

Related videos from verified sources

FDA Panel Meets to Determine COVID Booster Shot Strategy [Video]

FDA Panel Meets to Determine COVID Booster Shot Strategy

FDA Panel, Meets to Determine, COVID Booster Shot Strategy. FDA Panel, Meets to Determine, COVID Booster Shot Strategy. On April 6, United States Food and Drug Administration, advisers will meet to..

Credit: Wibbitz Top Stories     Duration: 01:31Published
What's Next for COVID-19 Vaccines? [Video]

What's Next for COVID-19 Vaccines?

What's Next for , COVID-19 Vaccines?. NPR reports most vaccinated Americans will soon be up for another round of coronavirus shots. Experts say as autumn approaches, immunity could be waning among..

Credit: Wibbitz Top Stories     Duration: 01:30Published